SEC Form 4 · accession 0001209191-18-034231
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Engelhart
Officer — Chief Financial Officer
Period of report
May 30, 2018
Accepted (ET)
May 30, 2018 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | May 30, 2018 | M | 5,000 | $0.61 | A | 5,000 | D | |
| Common Shares | May 30, 2018 | S | 5,000 | $35.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $0.61 | May 30, 2018 | M | 5,000 | D | — | Nov 25, 2024 | Common Shares | 5,000 | 17,500 | D |
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Immediately exercisable.